Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
[No authors listed]. YESCARTA Prescribing Information. YESCARTA. https://www.yescarta.com/files/yescarta-pi.pdf Accessed May 27, 2020
Rossi, 2018, Clinical response in ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma, may be influenced by characteristics of the pretreatment tumor microenvironment (TME), Clin Lymphoma Myeloma Leuk, 18, 10.1016/j.clml.2018.07.213
Rossi, 2019, Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1, Cancer Res, 79
Locke, 2017, Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19), Cancer Res, 77
Habermann, 2012, New developments in the management of diffuse large B-cell lymphoma, Hematology, 17 Suppl 1, S93, 10.1179/102453312X13336169156014
Obstfeld, 2017, Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights, Blood, 130, 2569, 10.1182/blood-2017-08-802413
Hashwah, 2019, The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma, EMBO Mol Med, 11, 10.15252/emmm.201910576
Patel, 2019, The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative, Blood, 134, 2059